Klaus Hans Metzeler

← Back to Leipzig University

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. Stem cell gene expression programs influence clinical outcome in human leukemia

   2011 · 1,041 citations

2. A 17-gene stemness score for rapid determination of risk in acute leukaemia

   2016 · 902 citations

3. IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

   2010 · 763 citations

4. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

   2016 · 529 citations

5. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

   2008 · 438 citations

6. Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

   2012 · 406 citations

7. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML

   2018 · 336 citations

8. TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

   2011 · 316 citations

9. Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome

   2009 · 293 citations

10. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

    2011 · 275 citations

11. RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

    2012 · 268 citations

12. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

    2015 · 253 citations

13. Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

    2012 · 251 citations

14. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

    2010 · 225 citations

15. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

    2011 · 210 citations

16. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

    2013 · 208 citations

17. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia

    2020 · 192 citations

18. Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients

    2013 · 183 citations

19. Prognostic Significance of Expression of a Single MicroRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

    2010 · 182 citations

20. Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis

    2016 · 167 citations

21. Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score

    2013 · 151 citations

22. A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia

    2017 · 139 citations

23. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia

    2018 · 138 citations

24. ERG Expression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis of ERG, MN1, and BAALC Transcript Levels Using Oligonucleotide Microarrays

    2009 · 130 citations

25. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older

    2018 · 122 citations

← Return to the university profile